Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Structure Therapeutics has raised $747.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Structure Therapeutics's investors include HSG, Qiming Venture Partners, Cormorant Asset Management, Lilly Asia Ventures, Janus Henderson Investors.
Structure Therapeutics is headquartered in South San Francisco, United States.
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Structure Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Structure Therapeutics — Funding & Investors." VCBacked, December 9, 2025, https://www.vcbacked.co/company/structure-therapeutics. Accessed October 17, 2026.
VCBacked. (2025). Structure Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/structure-therapeutics
{{cite web |title=Structure Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/structure-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated